Intravenous immunoglobulin (IVIG): Modes of action in the clinical management of recurrent pregnancy loss (RPL) and selected autoimmune disorders

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 4, 2004, Pages 359-370

  Omwandho, Charles O A ^a   Gruessner, Susanne E M ^b   Roberts, Timothy K ^c   Tinneberg, Hans Rudolf ^b  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Autoimmune disorders; Intravenous immunoglobulin; Recurrent pregnancy loss

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; HERPES ZOSTER IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTRAGLOBULIN; MEMBRANE PHOSPHOLIPID; METHYLPREDNISOLONE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAGLOBULIN; PREDNISOLONE; PREDNISONE; STEROID; VARITEC;

ALLOIMMUNITY; ANAPHYLAXIS; ANXIETY DISORDER; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACKACHE; BLOOD VISCOSITY; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; EATON LAMBERT SYNDROME; ECONOMIC ASPECT; FEMALE; FETUS DISEASE; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; KIDNEY ALLOGRAFT REJECTION; MENTAL STRESS; METABOLIC DISORDER; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYASTHENIA GRAVIS; NAUSEA; NEWBORN HEMOLYTIC DISEASE; PRIORITY JOURNAL; PRURITUS; RECURRENT ABORTION; REVIEW; RHEUMATOID ARTHRITIS; SHIVERING; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TROPHOBLAST; VOMITING;

ABORTION, HABITUAL; AUTOIMMUNE DISEASES; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 2342639722     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.065     Document Type: Review

References (100)

1. Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin North Am 1997;81:151-77.
2. Lockshin MD. Antiphospholipid antibody syndrome? Rhem Dis Clin North Am 1994;20:45-59.
3. Adler RR, Ak NG, Rote NS. Monoclonal antiphosphatidyl serine antibody inhibits intracellular fusion of the choriocarcinoma cell line JAR. Biol Reprod 1995;53:905-10.
4. Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote NS. Monoclonal antibody against phosphatidyl serine inhibits in vitro human trophoblast hormone production and invasion. Biol Reprod 1997;56:50-8.
5. Geva E, Amit A, Lerner-Gera L, Lessing JB. Autoimmunity and reproduction. Fertil Steril 1997;67:599-611.
6. Malinowski A, Wilczynski J, Zeman K, Glawacka E, Kolasa D, Szpakowski A, et al. Immunological characteristics of nonpregnant women with unexplained recurrent spontaneous abortion who underwent paternal lymphocyte immunization. Zentralbl Gynakol 1998;120:493-502.
7. Christiansen OB. A fresh look at the causes and treatment of recurrent miscarriage, especially its immunological aspects. Hum Reprod Update 1996;2:271-93.
8. MacLeod AM, Power DA, Mason RJ, Stewart KN, Shewan WG, Edward N, et al. Possible mechanisms of action of transfusion effect in renal transplantation. Lancet 1982;2:468-70.
9. MacLeod AM, Mason RJ, Stewart KN, Power DA, Shewan WG, Edward N, et al. Association of Fc receptor-blocking antibodies and human renal transplant survival. Transplantation 1982;34:273-9.
10. Combe B, Cosso B, Clot J, Bonneau M, Sany J. Human placenta-eluted gamma globulins in immunomodulating treatment of rheumatoid arthritis. Am J Med 1985;78:920-8.
11. Ellis SA, Palmer MS, McMichael AJ. Human trophoblast and the choriocarcinoma cell line BeWo express a truncated HLA class I molecule. J Immunol 1990;144:731-5.
12. Szekeres-Bartho J, Par G, Dombay GY, Smart YC, Volgyi Z. The anti abortive effect of progesterone induced blocking factor in mice is manifested by modulating NK activtity. Cell Immunol 1997;177:194-9.
13. Malan-Borel I, Gentile I, Angelucci J, Pividori J, Guala MC, Binagli RA, et al. Asymmetric molecules with antipaternal activity isolated from sera and placenta of pregnant women. J Reprod Immunol 1991;20:129-40.
14. Wright-Kanuth MS, Smith LA. Developments in component therapy: novel components and new uses for familiar preparations. Clin Lab Sci 2002;15:116-24.
15. Wahn V, editor. Klinischer Einsatz von intravenösen Immunoglobulinen. Bremen: Uni-Med, 2000:21-35.
16. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-6.
17. Crow AR, Song S, Semple JW, Freedman J, Lazarus AH. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotypic reactivity. Br J Haematol 2001;115:679-86.
18. Bruhns, Samuelsson A, Pollard JW, Ravetch JV. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003;18:573-81.
19. Abe Y, Horiuchi A, Miyake M, Kimura S. Anticytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5-19.
20. Ross C, Stevenson M, Hansen MB, Veulsgaard GL, Bendtzen K. Specific autoantibodies directed against interferon-a in pharmaceutically prepared human immunoglobulin preparations. J Interferon Res 1994;14:159-60.
21. Emmenegger U, Frey U, Reimers A, Fux C, Semela D, Cottagnoud P, et al. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol 2001;68:4-10.
22. Yu Z, Lennon VA. Mechanisms of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340:227-8.
23. Hansen RJ, Balthasar JP. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 2003;92:1206-15.
24. Graphou O, Chioti A, Pantazi A, Tsekoura C, Kontopoulou V, Georgiadou E, et al. Effect of intravenous immunoglobulin treatment on the Th1/Th2 balance in women with recurrent spontaneous abortions. Am J Reprod Immunol 2003;49:21-9.
25. Pricop L, Redecha P, Teillaud JL, Frey J, Fridman WH, Sautes-Fridman C, et al. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol 2001;166:531-7.
26. Sharief MK, Ingram DA, Swash M, Thompson EJ. I.v. immunoglobulin reduces circulating preinflammatory cytokines in Guillain-Barre' syndrome. Neurology 1999;52:1833-8.
27. Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute complement-dependent immune damage in a guinea pig model. J Clin Invest 1989;84:1974-81.
28. Lutz HU, Stammler P, Jelezarova E, Nater M, Späth PJ. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996;88:184-93.
29. Lutz HU, Stammler P, Späth PJ, Hess-Schmid M, Trueb RM, Jelezarova E. High dose pooled human IgG (IVIG) has a complement attenuating effect in vivo in an inflammatory disease. Mol Immunol 1998;35:368.
30. Binstadt BA, Geha RS, Bonilla FA. IgG Fc receptor polymorphism in human disease: implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol 2003;111:697-703.
31. Simon HU, Späth PJ. IVIG-mechanisms of action. Allergy 2003;58:543-52.
32. De Placido G, Zullo F, Mollo A, Cappiello F, Nazzaro A, Colacurci N, et al. Intravenous immunoglobulin (IVIG) in the prevention of implantation failures. Ann N Y Acad Sci 1994;734:232-4.
33. Sigman K, Ghibu F, Sommerville W, Toledano BJ, Bastein Y, Cameron L, et al. Intravenous immunoglobulin inhibits IgE production in human B lymphocytes. J Allergy Clin Immunol 1998;102:421-7.
34. Christiansen OB, Mathiesen O, Lauristen JG, Grunnet N. Intravenous immunoglobulin treatment of women with multiple miscarriages. Human Reprod 1992;7:718-22.
35. Kwak JY, Kwak FM, Ainbinder SW, Ruiz AM, Beer AE. Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortions. Am J Reprod Immunol 1996;35:363-9.
36. Ruiz JE, Kwak JY, Baum L, Gilman-Sachs A, Beaman KD, Kim YB, et al. Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with recurrent spontaneous abortion. Am J Reprod Immunol 1996;35:370-5.
37. Maruyama T, Makino T, Iwasaki K, Sugi T, Umeuchi M, Ozawa N, et al. The influence of intravenous immunoglobulin treatment on maternal immunity in women with unexplained recurrent miscarriage. Am J Reprod Immunol 1994;31:7-18.
38. Nydegger UE. Hypothetic and established action mechanisms of therapy with immunoglobulin G. In: Imbach P, editor. Immunotherapy with intravenous immunoglobulins. New York London: Academic Press, 1991:27-36.
39. Dupont E, Moriaux M, Lambermont M, Englert Y. Reevaluation of immunomodulator treatment for recurrent abortions. Rev Med Brux 1998;19:69-72.
40. Malinowski A, Szpakowski M, Wilczynski J, Oszukowski P, Wozniak P. Efficiency of paternal lymphocyte immunization in prevention of unexplained recurrent spontaneous abortion I. Clinical prognostic factors. Gynekol Pol 1997;68:165-72.
41. Yamada H, Kishida T, Kobayashi N, Kato H, Hoshi N, Fujimoto S. Massive immunoglobulin treatment in women with four or more recurrent spontaneous primary abortions of unexplained etiology. Hum Reprod 1998;13:2620-3.
42. Coulam CB, Goodman C. Increased pregnancy rates after IVF/ET with intravenous immunoglobulin treatment in women with elevated circulating CD56+ cells. Early Pregnancy 2000;4:90-8.
43. Stricker RB, Steinleitner A, Bookoff CN, Weckstein LN, Winger EE. Successful treatment of immunological abortion with low dose intravenous immunoglobulin. Fertil Steril 2001;76:637-9.
44. Coulam BC, Krysa LJ, Stern JJ, Bustillo M. Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am J Reprod Immunol 1995;34:333-7.
45. Sher G, Feinman M, Zouves C, Kuttner G, Maassarani G, Salem R, et al. High fecundity rates following in vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Hum Reprod 1994;9:2278-83.
46. Sher G, Matzner W, Feinman, Maassarani G, Zouves C, Chong P, M, et al. The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody positive women undergoing in vitro fertilization. Am J Reprod Immunol 1998;40:74-8.
47. Sher G, Zouves C, Feinman M, Maassarani G, Matzner W, Chong P, et al. A rational basis for the use of combined heparin/aspirin and IVIG immunotherapy in the treatment of recurrent IVF failure associated with antiphospholipid antibodies. Am J Reprod Immunol 1998;39:391-4.
48. Mueller-Eckhardt G. Immunotherapy with intravenous immunoglobulin for prevention of recurrent pregnancy loss: European experience. Am J Reprod Immunol 1994;32:281-5.
49. Stephensen MD, Dreher K, Houlihan E, Wu V. Prevention of unexplained recurrent spontaneous abortion using intravenous immunoglobulin: a prospective, randomized, double blinded, placebo controlled trial. Am J Reprod Immunol 1998;39:82-8.
50. Omwandho CA, Tinneberg HR, Tumbo-Oeri AG, Roberts TK, Falconer J. Recurrent pregnancy losses and the role of immunotherapy. Arch Gynecol Obstet 2000;264:3-12.
51. Branch DW, Porter TF, Paidas MJ, Belfort MA, Gonik B. Obstetric uses of intravenous immunoglobulin: successes, failures, and promises. J Allergy Clin Immunol 2001;108Suppl:S133-8.
52. Bussel JB, Berkowitz RL, Lynch L, Lesser ML, Paidas MJ, Huang CL, et al. Antenatal management of alloimmune thrombocytopenia with intravenous immune globulin: a randomized trial of the addition of low dose steroid to intravenous immune globulin. Am J Obstet Gynecol 1996;174:1414-23.
53. Gaddipati S, Berkowitz RL, Lembet AA, Lapinski R, McFarland JG, Bussel JB. Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. Am J Obstet Gynecol 2001;185:976-80.
54. Porter TF, Silver RM, Jackson G, Branch DW, Scott JR. Intravenous immune globulin in the management of severe RHD hemolytic disease. Obstet Gynecol Surv 1997;52:193-7.
55. Ronda N, Hurez V, Kazatchkine MD. Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox Sang 1993;64:65-72.
56. Imbach P, Wagner HP, Berchtold W, Gaedicke G, Hirt A, Joller P, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985;2:464-8.
57. von dem Borne AEG, Vos JJE, Pegels JG, Thomas LL, van der Lelie. High dose intravenous methylprednisolone or high dose intravenous gamma globulin for autoimmune thrombocytopenia. Br Med J 1988;296:249-50.
58. Intravenous immunoglobulin therapy(IVIg) - a guide for purchasers and prescribers. In: NHS Northern and Yorkshire regional drug and therapeutics Centre, Wolfson Unit, Claremont Place, Newcastle upon Tyne NE2 4HH.
59. Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apheresis Sci 2003;28:249-55.
60. Van der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barre Study Group. A trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 1992;326:1123-29.
61. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome. Neurology 1996;46:100-3.
62. Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC; French Guillain-Barre Syndrome Cooperative Group. Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 2001;71:235-8.
63. Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barre syndrome after treatment with human immune globulin. Neurology 1993;43:872-5.
64. Bleck TP. IVIG for GBS: potential problems in the alphabet soup. Neurology 1993;43:857-8.
65. Dhillon R, Newton L, Rudd PT, Hall SM. Management of Kaeasaki disease in the British Isles. Arch Dis Child 1993;69:631-8.
66. Nishikawa M, Ichiyama T, Hasegawa M, Kawasaki K, Matsubara T, Furukawa S. Safety from thromboembolism using intravenous immunoglobulin therapy in Kawasaki disease: study of whole-blood viscosity. Pediatr Int 2003;45:156-8.
67. Shahar E, Leiderman M. Outcome of severe Guillain-Barre syndrome in children: comparison between untreated cases versus gamma-globulin therapy. Clin Neuropharmacol 2003;26:84-7.
68. Azulay JP, Verschueren A, Attarian S, Pouget J. Guillain-Barre syndrome and its frontiers. Rev Neurol (Paris) 2002;158:21-6.
69. Dyck PJ, Litchy W, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in CIDP. Ann Neurol 1994;36:838-45.
70. Ioannou Y, Isenberg DA. Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J 2002;599-6.
71. Schoenfeld Y, Rauova L, Gilburd B, Kvapil F, Goldberg I, Kopolovic J, et al. Efficacy of affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 2002;14:1303-11.
72. Zandman-Goddard G, Schoenfeld Y. Novel approaches to therapy for SLE. Clin Rev Allergy Immunol 2003;25:105-12.
73. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
74. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997;29:193-9.
75. Ait Benhaddou E, Birouk N, El Alaoui-Faris M, Mzalek-Tazi Z, Ai S, Belaidi H, et al. Acute Guillain-Barre-like polyradiculoneuritis revealing acute systemic lupus erythematosus: two case studies and review of literature. Rev Neurol (Paris) 2003;159:300-6.
76. Chunharas A, Nuntnarumit P, Hongeng S, Chaunsumrit A. Neonatal lupus erythematosus: clinical manifestations and management. J Med Assoc Thai 2002;Suppl 4:S1302-8.
77. Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, et al. A study of 20 SLE patients with intravenous immunoglobulin: clinical and serologic response. Lupus 1999;8:705-12.
78. Rauova L, Lukac J, Levy Y, Rovensky J, Shoenfeld Y. High-dose intravenous immunoglobulins for lupus nephritis - a salvage immunomodulation. Lupus 2001;10:209-13.
79. Nowak-Wegrzyn A, Lederman HM. Supply, use, and abuse of intravenous immunoglobulin. Curr Opin Pediatr 1999;11:533-9.
80. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-7.
81. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9.
82. NIH Consensus Conference: Intravenous immunoglobulin-prevention and treatment of disease. J Am Med Assoc 1990;264:3189-93.
83. Cosi V, Lombardi M, Piccolo G, Erbetta A. Treatment of myasthenia gravis with high dose intravenous immunoglobulin. Acta Neurol Scand 1991;84:81-4.
84. Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD. Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-immunoglobulin. Arch Neurol 1993;50:837-40.
85. Bain PG, Montomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton syndrome. Neurology 1996;47:678-83.
86. Cutolo M, Sulli A, Pizzorni C, Craviotto C, Straub RH. Hypothalamic-pituitary-adrenocorticoid and gonadal functions in rheumatoid arthritis. Ann NY Acad Sci 2003;992:107-17.
87. Edward D, Harris Jr. Clinical feature of rheumatoid arthritis. In: Kelley WN, Ruddy S, Harris ED, Sledge CB, editors. Textbook of rheumatology. Philadelphia: WB Saunders, 1997:999-5.
88. Maeda H, Furonaka K, Matsushima K, Awaya Y, Kuwabara M. Successful treatment of 'malignant rheumatoid arthritis' in Japan with pooled intravenous immunoglobulin. Rheumatology 2001;40:955-6.
89. Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E, et al. Randomized trial of intravenous immunoglobulin G, intravenous anti-D and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994;344:703-7.
90. Blanchette VS, Luke B, Andrew M, Sommerville-Nielsen S, Barnard D, de Veber B, et al. A prospective, randomized trial of high-dose intravenous immune globulin therapy, oral prednisone therapy and no therapy in childhood acute immune thrombocytopenic purpura. J Paediatr 1993;123:989-95.
91. Singhi SC, Jayshree M, Singhi P, Prabhakar S. Intravenous immunoglobulin in very severe childhood Guillain-Barre syndrome. Ann Trop Paediatr 1999;19:167-74.
92. Boralevi F, Barat P, Lepreux S, Stockman AL, Taieb A, Leauet-Labreze C. Kawasaki's disease with eruptive pustular and guttate psoriasis. Ann Dermatol Venereol 2003;130:528-31.
93. Alekseeva El, Shakhbazian IE, Zholobova KB. Effectiveness of systemic immunoglobulins in the treatment of the systemic variants of juvenile rheumatoid arthritis. Klin Med (Mosk) 2001;79:26-9.
94. Wegner B, Ahmed I. Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis. Clin Neurol Neurosurg 2002;105:3-8.
95. Huang CS, Hsu HS, Kao KP, Huang MH, Huang BS. Intravenous immunoglobulin in the preparation of thymectomy for myasthenia Gravis. Acta Neurol Scand 2003;108:136-8.
96. Rocha PN, Butterly DW, Greenberg A, Reddan DN, Tuttle-Newhal J, Collins BH, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003;75:1490-5.
97. Steinberger BA, Ford SM, Coleman TA. Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia. Am J Hematol 2003;73:97-100.
98. Leung DYM, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993;342:1385-8.
99. Horwitz MS, Sarvetnick N. Viruses, host responses, and autoimmunity. Immunol Rev 1999;169:241-53.
100. Bleeker WK, Teeling JL, Hack CE. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 2001;98:136-42.